LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 2, 2013, Pages 250-259

  Powell, David R ^a   Smith, Melinda ^a   Greer, Jennifer ^a   Harris, Angela ^a   Zhao, Sharon ^a   DaCosta, Christopher ^a   Mseeh, Faika ^a   Shadoan, Melanie K ^a   Sands, Arthur ^a   Zambrowicz, Brian ^a   Ding, Zhi Ming ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 CHLORO 3 (4 ETHOXYBENZYL)PHENYL) 6 (METHYLTHIO)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; ALPHA METHYLGLUCOSIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; LX 4211; PEPTIDE YY; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; COLON; CONTROLLED STUDY; DOSE RESPONSE; EMBRYO; GLUCOSE ABSORPTION; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMALL INTESTINE; TEST MEAL;

ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; DIET; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; GLYCOSIDES; GLYCOSURIA; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; METHYLGLUCOSIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE YY; POSTPRANDIAL PERIOD; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84876519168     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.203364     Document Type: Article

References (56)

1. Asmar M, Simonsen L, Madsbad S, Stallknecht B, Holst JJ, and Bülow J (2010) Glucose-dependent insulinotropic polypeptide may enhance fatty acid reesterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes 59:2160-2163.
2. Baggio LL and Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157. (Pubitemid 46711096)
3. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, and Ghatei MA, et al. (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650-654.
4. Brommage R, Desai U, Revelli JP, Donoviel DB, Fontenot GK, Dacosta CM, Smith DD, Kirkpatrick LL, Coker KJ, and Donoviel MS, et al. (2008) High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes. Obesity (Silver Spring) 16:2362-2367.
5. Cherbut C, Ferrier L, Rozé C, Anini Y, Blottière H, Lecannu G, and Galmiche JP (1998) Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat. Am J Physiol 275:G1415-G1422.
6. Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, Kim HS, Melvin DL, and Egan JM (2009) Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58:1342-1349.
7. Cummings DE (2009) Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond) 33 (Suppl 1):S33-S40.
8. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, and MacConell L (2008) Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. Curr Med Res Opin 24:2943-2952.
9. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, and Schwartz S (2012) Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 14:539-545.
10. Donoviel DB, Freed DD, Vogel H, Potter DG, Hawkins E, Barrish JP, Mathur BN, Turner CA, Geske R, and Montgomery CA, et al. (2001) Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN. Mol Cell Biol 21:4829-4836. (Pubitemid 32588261)
11. Dumoulin V, Moro F, Barcelo A, Dakka T, and Cuber JC (1998) Peptide YY, glucagonlike peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology 139:3780-3786. (Pubitemid 28512258)
12. Ehrenkranz JR, Lewis NG, Kahn CR, and Roth J (2005) Phlorizin: A review. Diabetes Metab Res Rev 21:31-38.
13. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, and Göke B (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22:283-291.
14. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, and Marks V (1993) Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns. J Endocrinol 138:159-166. (Pubitemid 23266831)
15. Flint A, Raben A, Astrup A, and Holst JJ (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520. (Pubitemid 28084232)
16. Fu-Cheng X, Anini Y, Chariot J, Voisin T, Galmiche JP, and Rozé C (1995) Peptide YY release after intraduodenal, intraileal, and intracolonic administration of nutrients in rats. Pflugers Arch 431:66-75.
17. Goodwin NC, Mabon R, Harrison BA, Shadoan MK, Almstead ZY, Xie Y, Healy J, Buhring LM, DaCosta CM, and Bardenhagen J, et al. (2009) Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. J Med Chem 52:6201-6204.
18. Gorboulev V, Schürmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, and Cunard R, et al. (2012) Na(1)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187-196.
19. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, and Göke B (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56:117-126.
20. Holman RR, Paul SK, Bethel MA, Matthews DR, and Neil HA (2008) 10-year followup of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589.
21. Huang ES, Basu A, O'Grady M, and Capretta JC (2009) Projecting the future diabetes population size and related costs for the U.S. Diabetes Care 32:2225-2229.
22. Ikumi Y, Kida T, Sakuma S, Yamashita S, and Akashi M (2008) Polymer-phloridzin conjugates as an anti-diabetic drug that inhibits glucose absorption through the Na1 /glucose cotransporter (SGLT1) in the small intestine. J Control Release 125:42-49. (Pubitemid 350198679)
23. Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, Zhao X, Moeckel GW, Samuel VT, and Whaley JM, et al. (2011) SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60:890-898.
24. Kim BJ, Carlson OD, Jang HJ, Elahi D, Berry C, and Egan JM (2005) Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab 90:6665-6671. (Pubitemid 41759330)
25. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, and Pfister M (2009) Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85:513-519.
26. Lin HV, Frassetto A, Kowalik EJ, Jr, Nawrocki AR, Lu MM, Kosinski JR, Hubert JA, Szeto D, Yao X, and Forrest G, et al. (2012) Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS ONE 7:e35240.
27. Moriya R, Shirakura T, Ito J, Mashiko S, and Seo T (2009) Activation of sodiumglucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab 297:E1358-E1365.
28. Mortensen K, Christensen LL, Holst JJ, and Orskov C (2003) GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 114: 189-196. (Pubitemid 36773884)
29. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, and Zinman B; American Diabetes Association; European Association for Study of Diabetes (2009) Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203.
30. Nilsson AC, Ostman EM, Holst JJ, and Björck IM (2008) Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast. J Nutr 138:732-739. (Pubitemid 351469417)
31. Parker HE, Habib AM, Rogers GJ, Gribble FM, and Reimann F (2009) Nutrientdependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52:289-298.
32. Powell DR, DaCosta C, Gay J, Ding Z-M, Smith M, Greer J, Doree D, Jeter-Jones S, Mseeh F, and Rodriguez LA, et al. (2013) Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab304:E117-E130.
33. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, and Sattar N (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 373:1765-1772.
34. Reimann F (2010) Molecular mechanisms underlying nutrient detection by incretinsecreting cells. Int Dairy J 20:236-242.
35. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, and Gribble FM (2008) Glucose sensing in L cells: A primary cell study. Cell Metab 8:532-539.
36. Richter B, Bandeira-Echtler E, Bergerhoff K, and Lerch CL (2008) Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev (2):CD006739.
37. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, and Levy P, et al. (2009) Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract 15:540-559.
38. Sakuma S, Teraoka Y, Sagawa T, Masaoka Y, Kataoka M, Yamashita S, Shirasaka Y, Tamai I, Ikumi Y, and Kida T, et al. (2010) Carboxyl group-terminated polyamidoamine dendrimers bearing glucosides inhibit intestinal hexose transportermediated D-glucose uptake. Eur J Pharm Biopharm 75:366-374.
39. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, and Rothenberg P (2011) Canagliflozin, a novel inhibitor of sodium glucose cotransporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13:669-672.
40. Shibazaki T, Tomae M, Ishikawa-Takemura Y, Fushimi N, Itoh F, Yamada M, and Isaji M (2012) KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 342:288-296.
41. Shin AC, Zheng H, Townsend RL, Sigalet DL, and Berthoud H-R (2010) Mealinduced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology 151:1588-1597.
42. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, and Snaith A (2011) Glucagonlike peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev (10):CD006423.
43. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, and Egan JM (2006) Human duodenal enteroendocrine cells: Source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 290:E550-E559. (Pubitemid 43671703)
44. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, and Gribble FM (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61:364-371.
45. Turner RC, Cull CA, Frighi V, and Holman RR; UK Prospective Diabetes Study (UKPDS) Group (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005-2012. (Pubitemid 29254858)
46. UK Prospective Diabetes Study (UKPDS) Group (1998a) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
47. UK Prospective Diabetes Study (UKPDS) Group (1998b) Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865.
48. Vilsbøll T, Krarup T, Madsbad S, and Holst JJ (2003) Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114:115-121. (Pubitemid 36773875)
49. Wallace TM and Matthews DR (2002) Coefficient of failure: A methodology for examining longitudinal beta-cell function in Type 2 diabetes. Diabet Med 19:465-469. (Pubitemid 34639156)
50. Wright EM, Loo DD, and Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733-794.
51. Wright EM and Turk E (2004) The sodium/glucose cotransport family SLC5. Pflugers Arch 447:510-518. (Pubitemid 38241437)
52. Wu T, Zhao BR, Bound MJ, Checklin HL, Bellon M, Little TJ, Young RL, Jones KL, Horowitz M, and Rayner CK (2012) Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans. Am J Clin Nutr 95:78-83.
53. Yoder SM, Yang Q, Kindel TL, and Tso P (2010) Differential responses of the incretin hormones GIP and GLP-1 to increasing doses of dietary carbohydrate but not dietary protein in lean rats. Am J Physiol Gastrointest Liver Physiol 299: G476-G485.
54. Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, and Mseeh F, et al. (2012) LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 92:158-169.
55. Zhou J, Hegsted M, McCutcheon KL, Keenan MJ, Xi X, Raggio AM, and Martin RJ (2006) Peptide YY and proglucagon mRNA expression patterns and regulation in the gut. Obesity (Silver Spring) 14:683-689. (Pubitemid 46219743)
56. Zhou J, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Shen L, Danna SC, Tripathy S, Hegsted M, and Keenan MJ (2008) Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab 295:E1160-E1166.